Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region
- PMID: 35578052
- DOI: 10.1007/s10549-022-06622-3
Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region
Abstract
Purpose: Breast cancer (BC) is the most common form of female cancer around the world. BC is mostly sporadic, and rarely hereditary. These hereditary forms are mostly BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndrome. BRCA1 and BRCA2 genes are large and had some recurrent mutations specific to some populations. Through this work we analyze the most recurrent mutations in Moroccan population and compared them to a large review of other BRCA1/2 spectrum mutations in the MENA region.
Methods: We report in this work a series of 163 unrelated patients (the largest series of Moroccan patients) with familial breast and/or ovarian cancer, selected among patients referred to our oncogenetic outpatient clinic, from 2006 to 2021. To identify genetic variants in these two genes, different genetic analysis strategies have been carried out, using Sanger Sequencing DNA or Target Panel Sequencing.
Results: Pathogenic variants were identified in 27.6% of patients. The most frequent mutation identified in our patients was the c.1310_1313delAAGA, BRCA2 (33%), and three other mutations seem more frequent in the Moroccan population (33%) of all reported patients: c.798_799delTT, BRCA1; and c.3279delC, BRCA1; and c.7234_7235insG in BRCA2 gene.
Conclusion: Through this work, we emphasize the importance of screening for BRCA1 and BRCA2 recurrent mutations in Moroccan patients. Other MENA (MENA: English-language acronym referring to the Middle East and North Africa region) countries had also some recurrent BRCA mutations, which will allow a fast and unexpensive first line genetic analysis and a precise molecular diagnosis. This will allow an adapted follow-up of the patients and a pre-symptomatic diagnosis of their relatives.
Keywords: BRCA1; BRCA2; MENA; Morocco; Mutation; Recurrent; Spetcrum.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.BMC Cancer. 2023 Apr 13;23(1):339. doi: 10.1186/s12885-023-10822-5. BMC Cancer. 2023. PMID: 37055759 Free PMC article.
-
High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control.BMC Res Notes. 2017 Jun 2;10(1):188. doi: 10.1186/s13104-017-2511-2. BMC Res Notes. 2017. PMID: 28577564 Free PMC article.
-
Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.BMC Cancer. 2022 Feb 25;22(1):208. doi: 10.1186/s12885-022-09181-4. BMC Cancer. 2022. PMID: 35216584 Free PMC article.
-
BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.Gynecol Oncol. 2012 Jun;125(3):687-92. doi: 10.1016/j.ygyno.2012.03.007. Epub 2012 Mar 13. Gynecol Oncol. 2012. PMID: 22425665
-
BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries.Breast Dis. 2012;34(1):1-8. doi: 10.3233/BD-130348. Breast Dis. 2012. PMID: 23697973
Cited by
-
Ex Vivo Chromosomal Radiosensitivity Testing in Patients with Pathological Germline Variants in Breast Cancer High-Susceptibility Genes BReast CAncer 1 and BReast CAncer 2.Curr Issues Mol Biol. 2023 Aug 10;45(8):6618-6633. doi: 10.3390/cimb45080418. Curr Issues Mol Biol. 2023. PMID: 37623237 Free PMC article.
-
A regionally based precision medicine implementation initiative in North Africa:The PerMediNA consortium.Transl Oncol. 2024 Jun;44:101940. doi: 10.1016/j.tranon.2024.101940. Epub 2024 Mar 26. Transl Oncol. 2024. PMID: 38537326 Free PMC article.
-
Novel sulfamethoxazole and 1-(2-fluorophenyl) piperazine derivatives as potential apoptotic and antiproliferative agents by inhibition of BCL2; design, synthesis, biological evaluation, and docking studies.3 Biotech. 2024 Nov;14(11):269. doi: 10.1007/s13205-024-04111-6. Epub 2024 Oct 15. 3 Biotech. 2024. PMID: 39421851
References
-
- Yoshida K, Miki Y (2004) Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95:866–871 - PubMed
-
- Tazzite A, Jouhadi H, Nadifi S, Aretini P, Falaschi E, Collavoli A, Benider A, Caligo MA (2012) BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants. Gynecol Oncol 125(3):687–692 - PubMed
-
- Laraqui A, Uhrhammer N, Rhaffouli HE, Sekhsokh Y, Lahlou-Amine I, Bajjou T, Hilali F, El Baghdadi J, Al Bouzidi A, Bakri Y, Amzazi S, Bignon YJ (2015) BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African. Dis Markers 2015:194293 - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous